Aβ42 oligomer-specific antibody ALZ-201 reduces the neurotoxicity of Alzheimer’s disease brain extracts

Table 1 Neuropathological classification of human brain tissue, demographics and protein content, including amyloid-β levels

Subject ID	Age	Gender	IHC		Protein content (mg/mL)	Aβ40 (pg/mg protein)	Aβ42 (pg/mg protein)
Subject ID	Age	Gender	Amyloid	p-Tau	Protein content (mg/mL)	Aβ40 (pg/mg protein)	Aβ42 (pg/mg protein)
CO1	87	Male	−	−	1.43	29.27	2.88
CO2	60	Male	−	−	1.22	35.63	2.99
CO3	62	Female	−	−	0.77	47.80	6.15
AD1	85	Female	+	+	0.87	214.94	75.63
AD2	95	Male	+	+	1.43	67.30	43.63
AD3	72	Male	+	+	2.49	44.12	43.32
AD4	80	Female	+	+	0.49	248.25	74.77
AD5	96	Female	+	+	1.71	393.83	86.28
AD6	86	Female	+	+	1.05	220.54	273.75
AD7	60	Male	+	+	1.99	210.23	159.43

Pathological human cases of Alzheimer’s disease (AD, Braak stages 4–5; n=7) and non-AD controls (CO, n=3) were confirmed in tissue samples from the temporo-parietal grey matter cortices/frontal cortex that typically are affected by AD pathology using immunohistochemistry [77, 78]. Aβ40 and Aβ42 levels in homogenised whole-brain extracts from corresponding patients were measured by MSD assay and normalised to the total protein content as per the BCA assay.

ISSN: 1758-9193